Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

In Partnership With:

Partner | Cancer Centers | <b>The Tisch Cancer Institute at Mount Sinai </b>

Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib from the BRUIN trial, the potential for CAR T-cell therapy as evidenced in the ZUMA-2 trial, and how immunotherapies such as glofitamab are expanding the treatment paradigm.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Joshua Brody, MD, the director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute in New York, New York. Dr Brody joined us to preview mantle cell lymphoma (MCL) data being presented at the 2022 ASH Annual Meeting and Exposition.

In our exclusive interview, Dr Brody discussed promising data on pirtobrutinib (LOXO-305) in MCL from the phase 1/2 BRUIN trial (NCT03740529), the potential for CAR T-cell therapy in MCL as evidenced in the phase 2 ZUMA-2 trial (NCT02601313), and how immunotherapies such as glofitamab are expanding the treatment paradigm.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.